Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 119

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 119
---
 T                     | ​                | ​                               |    594 | ​ | ​ |    994 |
| All others (2)                         | ​                | ​                               |    672 | ​ | ​ |  3,339 |
| Total R&D development expense          | ​                | ​                               |  6,415 | ​ | ​ | 13,159 |
| R&D personnel related expenses         | ​                | ​                               | 12,835 | ​ | ​ | 20,494 |
| R&D facility and depreciation expense  | ​                | ​                               |  2,765 | ​ | ​ |  3,777 |
| R&D consulting expenses                | ​                | ​                               |  3,286 | ​ | ​ |  4,312 |
| R&D lab supplies                       | ​                | ​                               |  8,267 | ​ | ​ | 16,438 |
| R&D other expense (3)                  | ​                | ​                               |  6,945 | ​ | ​ |  4,295 |
| Total research and development expense | ​                | $                               | 40,513 | ​ | $ | 62,475 |

| (1) | Includes sponsored research, license and clinical trial related costs |

| (2) | Includes the costs for long-term follow-up and programs that were terminated. |

| (3) | Includes services provided by uBriGene under the manufacturing services agreement. |

| (4) | Credits reflect the termination of the programs and refunds from vendors. |

Our research and development expenses may vary significantly from period to period depending on where we are in the development plans for our various programs, and the resources we have at the time to commit to those programs. The more significant costs impacting the level of expense include:

| ● | employee-related expenses, which include salaries and benefits; |

| ● | license fees and milestone payments related to in-licensed products and technology; |

| ● | expenses incurred under agreements with CROs, investigative sites and consultants that conduct our clinical trials and our preclinical activities; |

| ● | costs associated with non-clinical activities, and regulatory approvals. |

Gain on the Sale of Property and Equipment Gain on the sale of property and equipment for the year ended December 31, 2023, is attributable to the difference between the base proceeds of $6.0 million received upon the closing of the uBriGene transaction and the relative